Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
نویسندگان
1 Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
2 Department of Hematology-Oncology, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Endocrinology, Vali Asr Hospital, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
4 Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
doi
چکیده
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive ...
